FDA approval of semaglutide could help Novo Nordisk access unexploited obesity market
Before the end of the week, the FDA will reveal its verdict on Novo Nordisk's obesity treatment semaglutide. According to Sydbank analyst Søren Løntoft Hansen, this is a crucial approval for the Danish pharmaceutical company.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
On Friday at the latest, the US Food and Drug Administration (FDA) will decide whether to approve Novo Nordisk's molecule semaglutide for treating obesity.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk risks insulin shock on Chinese market
For subscribers
